Company Profile

DTx Pharma LLC (AKA: DTx Pharma Inc)
Profile last edited on: 2/28/24      CAGE: 7WYE4      UEI: QH4NQ868H5V7

Business Identifier: Novel RNA-?based therapeutics to treat genetic drivers of disease: leveraging fatty acids as targeting ligands to Eenable RNA medicines for novel therapeutic area
Year Founded
First Award
Latest Award
Program Status
Active (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3210 Merryfield Row
San Diego, CA 92121
   (732) 690-2035
Location: Single
Congr. District: 49
County: San Diego

Public Profile

Having been previously housed in JLABs San Diego, in July 2023 it was announced that Novartis - fairly actively involved with several SBIR firms over several years - had acquired DTx Pjarma for $100,000,000. SBIR involved since 2019, DTx Pharma is structured around utilization of fatty acids to enable the delivery of RNA therapeutics: described as enabling delivery of double stranded miRNA/siRNA therapeutics. This concept of RNA-based therapeutics as the modality of choice has not previously been explored in any depth relative to knowledge of fatty acid receptor pharmacology and knowledge gained from the successful development and commercialization of fatty acid-conjugated peptide therapeutics. The firm's technology is directly addressing what is described as the most important barrier to widespread use of oligos--finding safe and effective ways to get nucleic acids into cells and tissues outside of the liver. It is the objective of DTx Pharma management therefore to undertake development of the technology such that could unleash RNA-based therapeutics as the modality of choice for personalized treatment across most therapeutic areas solving some of the issues that limited previous-generation platforms, including poor pharmacokinetics and insufficient cellular uptake.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Arthur T Suckow -- CEO and Chief Scientific Officer

  Charles Allerson -- Vice President of Chemistry and Drug Development

  Denise Bevers -- Chief Operating Officer

  Jeff Friedman -- COO

  John Grundy -- Co-Founder

  Adam Pavlicek -- Co-Founder